Table 1 Ex vivo susceptibility to standard anti-malarial drugs of 32 Plasmodium falciparum isolates from Dakar collected from September 2014 to November 2015. The results were compared to the P. falciparum W2 clone tested under the same conditions
Drugs | Isolate IC50 mean [CI 95%] | W2 IC50 mean [CI 95%] | Resistance cut-off | % (no) of reduced susceptibility |
|---|---|---|---|---|
Monodesethylamodiaquine | 28.9 nM [21.3–39.0] | 75 nM [70–80] | 61 nM | 28.1 (9/32) |
Chloroquine | 62.2 nM [35.0–110.6] | 324 nM [199–351] | 77 nM | 46.9 (15/32) |
Lumefantrine | 3.5 nM [2.3–5.2] | 12.4 nM [9.7–18.3] | 115 nM | 0 (0/32) |
Mefloquine | 26.0 nM [18.4–36.7] | 18.3 nM [16.8–19.0] | 30 nM | 45.2 (14/31) |
Quinine | 220.6 nM [157.6–308.7] | 294 nM [277–314] | 611 nM | 9.7 (3/31) |
Piperaquine | 36.5 nM [26.5–50.4] | 31.5 nM [28.8–34.4] | 135 nM | 0 (0/30) |
Pyronaridine | 8.7 nM [5.8–13.2] | 26.0 nM [21.5–25.7] | 60 nM | 0 (0/30) |
Dihydroartemisinin | 1.54 nM [0.99–2.39] | 1.35 nM [1.14–1.60] | 12 nM | 0 (0/28) |
Artesunate | 2.13 nM [1.27–3.59] | 1.63 nM [1.41–1.92] | 12 nM | 0 (0/28) |
Doxycycline | 25.7 µM [19.5–33.9] | 11.3 µM [10.0–12.7] | 37 µM | 31.2 (10/32) |